How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the res...

Full description

Bibliographic Details
Main Authors: Treen Carson Michael Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee, Kwee Yong, Jamie D. Cavenagh, David A. Cairns, Alberto Alvarez-Iglesias, Gordon Cook
Format: Article
Language:English
Published: Atlantis Press 2021-02-01
Series:Clinical Hematology International
Subjects:
Myeloma
relapse
bortezomib
adriamycin
dexamethasone
response
Online Access:https://www.atlantis-press.com/article/125952406/view

Internet

https://www.atlantis-press.com/article/125952406/view

Similar Items